BioCryst Pharmaceuticals, Inc.
We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases.
We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases.
BioCryst Pharmaceuticals, Inc. is a global biotechnology company committed to enhancing the lives of individuals affected by complement-mediated and other rare diseases through the development of oral small-molecule and protein therapeutics. With a focus on structure-guided drug design, the company strives to introduce pioneering or top-of-the-line treatment options for challenging diseases. Based in Durham, North Carolina, BioCryst Pharmaceuticals operates as a commercial-stage biotech company, with its European headquarters located in Dublin, Ireland, and its Discovery Center of Excellence positioned in Birmingham, Alabama. The company boasts a widespread presence with numerous regional offices worldwide. Leveraging expertise in structure-guided drug design, BioCryst draws upon the collective strengths of its global workforce, which includes field professionals, laboratory researchers, and remote employees. Founded in 1986, the company recently secured a significant $450.00M Post-IPO Debt investment from Pharmakon Advisors on 17 April 2023. This influx of capital reflects investor confidence in BioCryst Pharmaceuticals' innovative approach and potential for impact in the biotechnology sphere.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $450.00M | 1 | Pharmakon Advisors | 17 Apr 2023 |
| Post-IPO Equity | $350.00M | 2 |
|
22 Nov 2021 |
| Post-IPO Debt | $325.00M | 2 |
|
07 Dec 2020 |
| Grant | $44.00M | - | 31 Aug 2020 | |
| Post-IPO Equity | $115.00M | - | 01 Jun 2020 |
No recent news or press coverage available for BioCryst Pharmaceuticals, Inc..
We care about your data, and we'd love to use cookies make your experience better.
